Pablo Peinado, Research Nurse Coordinator, has reviewed some key abstracts from the European Oncology Nursing Society (EONS15) meeting during ESMO 2022.  He shares his thoughts on the conclusions and implications for nursing practice.  Watch the video for the key highlights and download the slides for the detailed data.


Pablo Peinado, Research Nurse Coordinator, reviews key abstracts from EONS15:

  • Development and implementation of virtual pre-chemotherapy consultations Oakley C. (Oral presentation)
  • Three Stage Capacity: The consent process for systemic anticancer therapy (Abstract #1141)
  • Impact of diet on immune checkpoint blockade: Nurse-directed dietary intervention (Abstract #3222)

GU NURSES CONNECT Update from EONS15 at ESMO 2022

Hi everyone, my name is Pablo Peinado and I am a Research Nurse Coordinator at the GU unit at the Hospital Universitario Virgen de la Victoria, Málaga, Spain. In this newsletter, I would like to give you some highlights of the abstracts presented this year in ESMO 2022 and EONS15, on behalf of GU NURSES CONNECT.

This year the presentations were really interesting and I would like to tell you a bit more about the following ones: First of all, Development and implementation of virtual pre-chemotherapy consultations, presented by Catherine Oakley. Secondly, Three Stage Capacity: The consent process for systemic anticancer therapy, presented by Fiona Barret. The last one, Impact of diet on immune checkpoint blockade:  a nurse-directed dietary intervention, presented by Julie Malo.

In the first abstract, Catherine Oakley and her team showed how they have started an intervention group where they used digital tools such as short videos or interactive exercises to help both the patients and the nurses to give and receive better information regarding chemotherapy, immunotherapy or possible side effects before they start their treatments. The results of those interventions have been really positive, with really good feedback from the patients, their families, and cancer nurses, helping them to arrive better prepared to their first chemotherapy appointment.

Thanks to this intervention they have already changed their clinical practice, starting to train their staff to prepare new digital tools and identify patients who will benefit from this platform. This team has demonstrated a new way of using digital tools and platforms to improve our patient's preparations for their chemotherapy treatment, reducing the risk of suffering side effects, and the anxiety that comes with visiting a day treatment unit for the first time.

Regarding the second abstract, Fiona Barret and her team have developed a pilot study where they have divided the informed consent process for oncology patients in three different stages. With this process, the patient visits a senior medical oncologist, an oncology nurse and an oncology registrar, in 3 different appointments during 14 days. It gives to the patient and their families, enough time and information to understand their new treatment and the document that they are signing. The results have been really positive and the feedback from the patients has shown how they understood better the process and had enough time to give their consent in a more comprehensive way.

With this preliminary results, an interventional study is necessary, and I look forward to seeing it, so we could demonstrate if this new process will change our clinical practice, in one of the most important steps during our patient's treatment. The take-home message for this presentation would be the importance of the informed consent for our patients and how we should work to find a way where we make sure our patients understand the documents that they sign before they start their treatment.

In the third abstract, Julie Malo and her team have shown the importance of our microbiota in the efficacy of the treatments with chemotherapy and immunotherapy. With the results of their study, using the food frequency questionnaire, they generate a general view of the patient’s lifestyle. It showed an homogeneous and poor diet. At the same time, some types of food such as egg, coffee or rice were associated with a better clinical response in their patients.

Even if we know that it is necessary to study a lot more about the microbiota effects in these kinds of treatments, it is really important to know our patient’s lifestyle, in order to help them to modify it, and try to generate the best outcome possible for the treatment that they are receiving. This kind of research changes our clinical practice showing how we should focus, not only the treatment options for our patients but in the food and lifestyle that they are living, as this will affect their treatment outcomes.

Thank you for watching this newsletter video on behalf of GU NURSES CONNECT and please remember to go to the website and download the slides for more information.

Pablo Peinado is a Senior Research Nurse Coordinator at Hospital Universitario Virgen de la Victoria in Malaga, Spain.  Pablo gained his Nursing Degree at the University of Valencia in 2014 and moved to the UK where he worked as a surgical nurse for two years.  In 2016 he received his Clinical Trials master’s degree and started to work as a Haematology Research Nurse at Churchill Hospital, Oxford where he was in charge of conducting different clinical trials for haematology patients. Pablo moved back to Spain in 2017 to be part of a new GU tumour unit under Dr David Olmos at Hospital Virgen de la Victoria, Malaga and worked as an Oncology Research Nurse with GU patients diagnosed with prostate, bladder and kidney cancer, coordinating early and late phase clinical trials.  He has recently been promoted to lead a new Clinical Research Unit and is in charge of coordinating a unit where the objectives are to treat patients with the most advanced medications and provide a personalised approach to their disease so that they can participate more actively during their treatment, learning about their disease and understanding the process of their treatment.

GU NURSES CONNECT Update from ESMO 2022 and EONS15 (Español)

GU NURSES CONNECT ha resumido los aspectos más destacados de la enfermería oncológica de la ESMO 2022 y la Sociedad Europea de Enfermería Oncológica (EONS15).

Experts
Pablo Peinado
  • clock 7 MIN
  • calendar Oct 2022
  • Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Bayer
Programme summary
Go to Spanish version
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025

Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Prof. Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
conference-update Conference update
Oncology 
Highlights from ASCO 2025: BRAF-mutant and MSI-H/dMMR colorectal cancer (CRC)

Expert opinion on the latest practice-changing data

Experts
Prof. Dominik Modest, Dr Sara Lonardi
  • clock 5 MIN
  • calendar Jun 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only